Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
After lunch. Loading wall is up. It will erode.
Keep slapping. The move is coming
The bag is at 25 cents.
Gonna make a run at 9 cents
Looks like I got my answer. Major runner.
Dime today?
Why celebrate gaps when they need to be filled?
In 10 minutes we find out if the MM's still have control.
Definitely not.
Really happy with my position just in time. What a great company damn.
Let's go slap those 429's and start the ascent!
Nice bid let's go
Right on. Definitely long on this one. Better news each time it drops. Money maker.
Time for a move
I'm with you all. Loaded the boat big time.
WTF is going on here?
Not everyday - blockbuster news hits on the OTC and the pps stays relatively level for you to accumulate. Talk about lucK!!!
Wow were you wrong!
Will be a multi-day runner
Has at least .25 written all over it!!!
Chooooo choooooo!
Monster slaps.
Rest of week going to be insane
Oh boy! Jumped back in at right time! NICE NEWS!!!
Jumped back in today.
Being held virtually. AA saved my life. It's there for those who want.
They don't call.
Fine with me. Will run harder.
They can play these games all the way down to .001 - not selling.
Will they let it go after lunch? Possibly!
People starting to understand. Right place, right time.
Inspyr Therapeutics (NSPX)
Inspyr Therapeutics is an integrated clinical-stage biopharmaceutical company that is focused on developing targeted cancer therapeutics for the treatment of cancerous tumors, including breast, prostate, bladder, kidney, and lung cancer along with the development of novel therapies to treat cancer, inflammation, and other serious diseases.
Inspyr, like Gilead’s Remdesivir utilizes similar targeting of adenosine for a novel COVID-19 treatment. Inspyr merged with Lewis and Clark Pharmaceuticals several years ago and since then has developed a proprietary, industry-leading technology platform based on adenosine chemistry and biology and a broad pipeline of novel therapies. Their pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist.
insert-text-here
Well let's put it this way - not going anywhere until mid May. I'm not.
Tomorrow is another day.
Get it
At the bottom!!!??? LMAO
Except it isn't. Shorting and manipulation clearly evident here.
Red to green kind of afternoon.
Oversold for sure.
Someone is hungry for shares.